stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) Return on equity
Takeda Pharmaceutical Co.'s return on equity over the twelve months to 30 September 2026 was 0.00%, up 2.1 percentage points from fiscal 2026 (−2.12%). Over the past ten years it has ranged from −5.83% (fiscal 2015) to 9.27% (fiscal 2018); the current reading is higher than 17% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of −0.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2026 | −2.12% | (3.60) |
| FY2025 | 1.48% | (0.57) |
| FY2024 | 2.05% | (2.76) |
| FY2023 | 4.81% | 0.68 |
| FY2022 | 4.13% | (3.54) |
| FY2021 | 7.67% | 6.77 |
| FY2020 | 0.90% | (2.14) |
| FY2019 | 3.04% | (6.23) |
| FY2018 | 9.27% | 3.13 |
| FY2017 | 6.14% | 2.52 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ZTS Zoetis Inc. compare | 64.9% |
| NBIX Neurocrine Biosciences, Inc. compare | 20.4% |
| UTHR United Therapeutics Corporation compare | 19.1% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 6.65% |
| RDY Dr. Reddy's Laboratories Ltd compare | 6.60% |
| TAK Takeda Pharmaceutical Co. | 0.00% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| ELAN Elanco Animal Health Incorporated compare | −2.98% |
| VTRS Viatris Inc. compare | −4.21% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on TAK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement